story of the week
Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
Lancet Oncol 2024 Mar 01;25(3)308-316, S Siva, M Bressel, M Sidhom, S Sridharan, BGL Vanneste, R Davey, R Montgomery, J Ruben, F Foroudi, B Higgs, C Lin, A Raman, N Hardcastle, MS Hofman, R De Abreu Lourenco, M Shaw, P Mancuso, D Moon, LM Wong, N Lawrentschuk, S Wood, NR Brook, T Kron, J Martin, D PryorFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.